Author:
Kianersi Farzan,Ghanbari Heshmatollah,Naderi Beni Zahra,Naderi Beni Afsaneh
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Oncology
Reference16 articles.
1. Falavarjani KG, Nguyen QD (2013) Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond) 27(7):787–794
2. Sawada O, Kawamura H, Kakinoki M, Ohji M (2008) Vascular endothelial growth factor in fellow eyes of eyes injected with intravitreal bevacizumab. Graefes Arch Clin Exp Ophthalmol 246:1379–1381
3. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ (2007) Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 114:855–859
4. Wang D (2014) Kyung Seek Choi, and Sung Jin Lee. Serum Concentration of Vascular Endothelial Growth Factor after Bilateral Intravitreal Injection of Bevacizumab -Korean J Ophthalmol. 28(1):32–38
5. E Rosen, A Rubowitz and J R Ferencz..Exposure to verteporfin and bevacizumab therapy for choroidal neovascularization secondary to punctate inner choroidopathy during pregnancy. Eye (2009) 23, 1479; doi: 10.1038/eye.2008.218
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献